For: | Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v26/i15/1805.htm |
Number | Citing Articles |
1 |
Zhongqi Sun, Zhongxing Shi, Yanjie Xin, Sheng Zhao, Hao Jiang, Jinping Li, Jiaping Li, Huijie Jiang. Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma. Academic Radiology 2023; 30: S81 doi: 10.1016/j.acra.2022.12.031
|
2 |
Wei Zhang, Hui-Fang Kong, Xu-Dong Gao, Zheng Dong, Ying Lu, Jia-Gan Huang, Hong Li, Yong-Ping Yang. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma. World Journal of Gastroenterology 2020; 26(35): 5287-5301 doi: 10.3748/wjg.v26.i35.5287
|
3 |
Ji Hoon Kim, Jin Hyoung Kim, Hyun-Ki Yoon, Gi-Young Ko, Ji Hoon Shin, Dong Il Gwon, Heung-Kyu Ko, Hee Ho Chu, Seong Ho Kim, Gun Ha Kim, Yonghun Kim, Shakir Aljerdah. Transarterial chemoembolization for advanced hepatocellular carcinoma without macrovascular invasion or extrahepatic metastasis: analysis of factors prognostic of clinical outcomes. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1072922
|
4 |
Apichat Kaewdech, Pimsiri Sripongpun, Natcha Cheewasereechon, Sawangpong Jandee, Naichaya Chamroonkul, Teerha Piratvisuth. Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients. Clinical and Translational Gastroenterology 2021; 12(2): e00310 doi: 10.14309/ctg.0000000000000310
|
5 |
Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han. Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1405178
|